Bicara Therapeutics (BCAX) EBT (2023 - 2026)

Bicara Therapeutics' EBT history runs 4 years deep, the most recent figure standing at -$56.2 million for Q1 2026.

• On a quarterly basis, EBT fell 52.71% year-over-year to -$56.2 million in Q1 2026; TTM through Mar 2026 was -$157.1 million, a 70.64% decrease from a year earlier, with the FY2025 full-year figure at -$137.7 million, down 103.12% from the prior year.
• EBT retreated to -$56.2 million in Q1 2026 per BCAX's latest filing, from -$37.3 million in the prior quarter.
• Across five years, EBT topped out at -$12.4 million in Q4 2023 and bottomed at -$56.2 million in Q1 2026.
• The 4-year median for EBT is -$22.8 million (2023), against an average of -$27.0 million.
• Across the five-year window, EBT gained 23.48% in 2024 and slumped 194.03% in 2025, its largest moves.
• Year by year, EBT stood at -$12.4 million in 2023, then tumbled by 67.04% to -$20.8 million in 2024, then slumped by 79.74% to -$37.3 million in 2025, then slumped by 50.43% to -$56.2 million in 2026.
• Per Business Quant, the three latest BCAX EBT figures stand at -$56.2 million (Q1 2026), -$37.3 million (Q4 2025), and -$36.3 million (Q3 2025).